GlaxoSmithKline Net Income Common Stock Trend from 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC Net Income Common Stock is decreasing with stable movements from year to year. Net Income Common Stock is predicted to flatten to about 4.1 B. For the period between 2010 and 2020, GlaxoSmithKline PLC, Net Income Common Stock quarterly trend regression had mean deviation of 1,503,270,117 and r-value of (0.31). GlaxoSmithKline PLC Operating Expenses is increasing as compared to previous years. The last year's value of Operating Expenses was reported at 14.93 Billion. The current Revenues is estimated to increase to about 33.9 B, while Cost of Revenue is projected to decrease to under 11.4 B.

Search Historical Trends

 
Refresh
Check GlaxoSmithKline PLC financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 10 B, Consolidated Income of 4.6 B or Cost of Revenue of 11.4 B, as well as many exotic indicators such as Interest Coverage of 158, Long Term Debt to Equity of 2.7 or Calculated Tax Rate of 23.02. This can be a perfect complement to check GlaxoSmithKline PLC Valuation or Volatility. It can also complement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation with competitors.

GlaxoSmithKline Net Income Common Stock Marginal Breakdown

Showing smoothed Net Income Common Stock of GlaxoSmithKline PLC with missing and latest data points interpolated. The amount of net income (loss) for the period due to common shareholders. Typically differs from Net Income to the parent entity due to the deduction of Preferred Dividends.
Net Income Common Stock10 Years Trend
Decreasing
Stable
 Net Income Common Stock 
      Timeline 

GlaxoSmithKline Net Income Common Stock Regression Statistics

Arithmetic Mean 4,245,502,392
Geometric Mean 3,662,464,739
Coefficient Of Variation 48.70
Mean Deviation 1,503,270,117
Median 4,499,000,000
Standard Deviation 2,067,764,923
Range 7,510,000,000
R-Value(0.31)
R-Squared 0.1
Significance 0.35
Slope(195,494,258)

GlaxoSmithKline Net Income Common Stock Over Time

20105.5 B
20115.2 B
20124.5 B
20135.4 B
20142.8 B
20158.4 B
2016912 M
20171.5 B
20183.6 B
20194.6 B
20204.1 B

Other Fundumenentals of GlaxoSmithKline PLC

About GlaxoSmithKline PLC Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Net Income Common Stock, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation with competitors. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page